Triflusal Triflusal Triflusal is a platelet aggregation inhibitor that was discovered and developed in the Uriach Laboratories, and commercialised in Spain since 1981. Currently, it is available in 25 countries in Europe, Asia, Africa and America. It is a drug of the salicylate family but it is not a derivative of acetylsalicylic acid (ASA). Trade names include Disgren, Grendis, Aflen and Triflux. Triflusal is a selective platelet antiaggregant through; Triflusal is indicated for; In the 2008 guidelines for stroke management from the European Stroke Organization, triflusal was for the first time recommended as lone therapy, as an alternative to acetylsalicylic acid
Tetrolic acid Tetrolic acid Tetrolic acid (2-butynoic acid) is a short-chain unsaturated carboxylic acid, described by the formula CH-C≡C-COH. Salts and esters of tetrolic acid are known as tetrolates. The first reported synthesis of tetrolic acid is believed to be by German chemist Johann Georg Anton Geuther in 1871 as part of his work investigating the derivatives of ethyl acetoacetate. Tetrolic acid is manufactured on a commercial scale by treatment of propyne with a strong base (to form an acetylide), followed by carbon dioxide: Strong bases such as "n"-BuLi and NaNH can be used. Tetrolic acid is highly soluble in polar solvents